BackgroundThe potential use of microRNAs (miRNAs) as ideal tumor markers has been the focus of recent research.ObjectiveOur hypothesis was that circulating miRNAs are differentially expressed in pretherapeutic sera of breast cancer patients compared to controls.Materials and MethodsUsing real-time quantitative polymerase chain reaction (qPCR) analysis, levels of 5 candidate miRNAs (miR10b, miR34a, miR155, miR195 and miR16) were quantified in sera of breast cancer patients and control individuals.ResultsLevels of preoperative sera showed significant upregulation of 3.36 fold rise in miR10b (p<0.001), a 2.07 fold rise in miR155 (p =0.005) and remarkable over expression of 11.9 fold rise in miR195 (p<0.001) of cases than controls. There was significant down regulation of miR34a (0.032, p<0.001). The comparison with the clinicopathological data of the breast cancer patients revealed significant high serum level of miR155 (p =0.004) and miR195 (p =0.002) in patients with lymph node metastasis and higher levels of miR10b (p =0.001) and miR155 (p <0.001) with distant metastasis (M1) than without metastasis (M0), in addition to significant decrease in miR34a (p <0.001) level in M1 than M0 cases.ConclusionsThese findings suggest that systemic circulating miRNAs have potential use as novel biomarkers for breast cancer.

No abstract

No abstract

We propose a method of crosslinking multiwalled carbon nanotubes (MWCNTs) with cotton fabric. 3-Glycidoxypropyltrimethoxy silane (GPTMS) polymer was used for the stabilization and modification of the surfaces of MWCNTs. The presence of tannic acid in the finishing formulation adds a sustainable functionality to the treated surface. The formation of the GPTMS–MWCNTs nanocomposite as well as the MWCNTs–GPTMS tannic-epoxy nanocomposite on the fabric surface was confirmed by Fourier-transform infrared spectra (FTIR). The surface morphology and physical properties were investigated. An assessment of antibacterial activity, UV-protective properties, and electrical conductivity was performed. The post-treatment results of the MWCNTs–GPTMS nanocomposite fabric with tannic acid exhibited superior antibacterial character with the highest inhibition zones for Staphylococcus aureus and Escherichia coli (26 mm, 24 mm). On the contrary, the electrical conductivity was negatively impacted. The treatment of cotton fabric with tannic acid showed a great UV-protection-factor estimation of 96.2, which was additionally improved by treatment with MWCNTs 152.1. Cotton fabric treated with cotton/GPTMS/tannic acid/MWCNTs as well as cotton/GPTMS/MWCNTs recorded the highest electrical-conductivity properties. Fabrication of MWCNTs–GPTMS/tannic-acid-nanocomposite-coated cotton fabric for durable antibacterial and UV protection with improved electrical and physical properties was successfully achieved.

Background and Aims: Inflammatory bowel diseases (IBD) have been reported to be caused by a complex interplay of immunological, infectious, and genetic factors. Previous studies have suggested that adipokines play a role in IBD by inducing proinflammatory cytokines. We aimed to evaluate the role of visfatin in the diagnosis algorithm of active IBD. Methods: 85 newly diagnosed IBD patients [56 diagnosed with ulcerative colitis (UC) and 29 with Crohn‘s disease (CD)] and 30 healthy controls were included. IBD phenotypes were described accordingly to Montreal classification. Hemoglobin, total leucocytic count (TLC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), albumin, fecal calprotectin and serum visfatin were measured. Results: The serum visfatin level was found to be significantly higher in patients with IBD than those in the control group (p<0.001). It was significantly positively correlated with CRP, ESR, and FC in both IBD groups. Receiver operating characteristic curve analysis of visfatin in diagnosis of UC revealed an area under curve of 0.911. At cutoff ≥1.4 ng/ml, the sensitivity was 92.9% and the specificity was 86.7%.. In CD group, at the same cutoff, AUC was 0.974, sensitivity was 96.6% and specificity was 86.7%. There was a statistically significant elevation of serum visfatin in extensive UC (E3) as compared to the other groups. A cutoff ≥3.25 ng/ml revealed 88.9% sensitivity, and 100% specificity in detection of E3 UC. Serum visfatin was significantly increased in CD stricturing phenotype (B2) as compared to non-stricturing non-penetrating CD (B1). A cutoff ≥3.5 ng/ml revealed 83.3% sensitivity, and 100% specificity in detection of B2. Conclusions: The serum visfatin level were significantly higher in patients with IBD than in controls. Serum visfatin might be a novel noninvasive marker to detect activity in IBD patients and can be used as predictor of disease extension in patients with UC.